The Food and Drug Administration launched the evaluation of the “Complementary Door” for the use of healthy yuan ditch oil

Although claiming to have used raw oil blended with cooking oil as a raw material without any knowledge, they stated that they would assume all responsibility if quality problems occur, but they still failed to save the market. On the day of the resumption of trading on the 31st, the stock price of Healthy Yuan (600380) (600380) firmly sealed the daily limit.

On August 31, the State Food and Drug Administration announced that it is organizing experts to retrieve relevant domestic and foreign literature to assess the impact of soybean oil quality on the quality and safety of cephalosporin antibiotic drugs, and has sent an investigation team to investigate.

The company "shouted"

Subsidiary Jiaozuo Health Yuan was suspected of purchasing 145 million yuan of blended oil as a raw material for production, pushing the Health Yuan to the cusp of public opinion. The impact of the incident far exceeded Zhu Baoguo’s expectations.

"In November last year, after learning that Henan Huikang Oil Company was investigated, the company consulted with relevant departments and received a reply that Health Yuan is also one of the victims." Zhu Baoguo said that due to the internal and external inspection data , Jiaozuo health yuan production of chemical raw materials 7-ACA quality was not affected by any, and Jiaozuo health yuan has also changed soybean oil buyers, so the company did not disclose the matter.

The subsequent development of the incident made the Health Yuan regret it. Due to the large amount of purchases, Jiaozuo Health Yuan became a target of public criticism after Henan Huikang Oil & Fat Co., Ltd. was suspected of selling inferior oil. "Because of the lack of effective detection methods and the lack of procurement management, Health Element has been exploited by poor suppliers in the production of chemical raw materials. We assume any quality responsibility resulting from this." Zhu Baoguo said that poor suppliers are blending in soybean oil. A certain percentage of inferior oils are still not detected in China by effective detection methods. It is understood that Health Yuan will check the purchased soybean oil batch by batch. In addition to testing the acid value and peroxide value according to the "National Standard for Testing Organic Soybean Oil Quality," the company will additionally increase the freezing test, oleic acid, etc. In the four enterprise standards tests, none of the soybean oils supplied by Wellcome Oil & Fat Co. was found to contain inferior product oils.

In fact, the health element is just one of the companies that “put a gun in the back”. According to reports, Henan Huikang Oil & Fat Co., Ltd. combines "drain oil" and normal soybean oil according to a certain ratio, and sells the blended soybean oil to the food, feed, and pharmaceutical raw material production enterprises in the name of normal soybean oil. Up to 62 downstream enterprises . According to sources, Huikang Oil & Fat Company has done a very wide range of damages. "Fighting oil" has not only flowed into some fermented pharmaceutical raw material enterprises in North China, but also has been purchased by some of the well-known food and feed companies in China.

The involvement of the Food and Drug Administration in food quality and safety issues has always been a hot spot for all walks of life, and the link between “ditch oil” and “pharmaceuticals” has triggered the “Mars hit the earth” effect. According to a statement issued by the State Food and Drug Administration, the reference to "ditch oil pharmaceuticals" is not appropriate and it is easy for the public to misunderstand.

On August 31st, the State Food and Drug Administration stated that it would pay high attention to the use of soybean oil mixed with "ditch oil" by companies and produce 7-ACA and sell it to pharmaceutical companies. An investigation team has been dispatched to investigate the situation. Pharmaceutical companies must strictly control the purchased raw materials according to regulations, conduct audits on supply companies, and prevent unqualified chemical raw materials from entering the pharmaceutical sector.

According to reports, 7-ACA is an intermediate for the production of cephalosporins and belongs to chemical raw materials. There are two steps in the production of 7-ACA by chemical companies: First, cephalosporin C is obtained through cephalosporin fermentation. Soybean oil is one of the components of the fermentation process. Soybean oil spiked with "flood oil" is used in this step. In the second step, 7-ACA is separated and purified by enzymatic or chemical cleavage. The production of cephalosporin antibiotics by pharmaceutical companies using 7-ACA also requires complicated and elaborate manufacturing processes, including derivatization, protection, access to side chains, deprotection and salt formation, as well as separation and purification, recrystallization and other steps to become cephalosporin antibiotics. The raw material medicine, through the preparation process, can produce oral and injection cephalosporin antibiotic drugs.

At present, the State Food and Drug Administration is organizing experts to retrieve relevant domestic and foreign literature to assess the impact of soybean oil quality on the quality and safety of cephalosporin antibiotics and to understand the practice of using recycled oil abroad. Experts believe that the formulation of “ditch oil pharmaceuticals” is not appropriate, and it is easy for the public to misunderstand; at the same time, antibiotic drugs have a long production chain and many links, and any link to adulteration should be condemned and bear responsibility.

The State Food and Drug Administration requires drug manufacturers to take effective measures to prevent unqualified raw materials from flowing into the production process, and at the same time strengthen the inspection of raw and auxiliary materials for fats and oils to ensure that the quality of drugs is safe and effective.

According to the previous health element, 7-ACA does not fall under the category of drug administration. However, this matter still caused the State Food and Drug Administration's attention.

The State Food and Drug Administration said on August 31 that an investigation team had been dispatched to conduct investigations. At the same time, the pharmaceutical companies were required to strictly monitor the purchased raw materials according to the regulations, conduct audits on supply companies, and prevent unqualified chemical raw materials from entering the pharmaceutical sector. At the same time, the State Food and Drug Administration also quoted experts as saying that the reference to "ditch oil pharmaceuticals" was inappropriate and it was easy for the public to misunderstand.

Focused on the healthy yuan suspect purchase billion yuan of oil for the pharmaceutical process, Henan Jiaozuo City Government issued a notice on September 1, said the investigation team has been set up in the enterprise. The results of the investigation will be announced in the near future.

However, it is worth noting that the use of 7-ACA produced by soybean oil supplemented with “ditch oil” components does not cause problems in the tests. Under such circumstances, how do pharmaceutical companies keep skepticism?

Pharmaceutical companies can hardly refuse "qualified" products. "In the absence of a clear test method and standard, if it is known that the other party is using waste oil to produce 7-ACA, no matter whether it is qualified or not, it will certainly not purchase. However, the problem is that The final test of 7-A CA produced by others is qualified.” The general manager of a pharmaceutical company in Guangdong said that he said that there is a long process between the intermediates and the raw materials and the preparations.